title: [A case of HER2-positive and AFP-producing gastric cancer successfully treated by trastuzumab/docetaxel/S-1 combination therapy].
abstract: A 74-year-old man was referred to our hospital because of abdominal distension. Upper gastrointestinal endoscopy revealed advanced gastric cancer and early gastric cancer. HER2-positive and AFP-producing gastric cancer with peritonitis carcinomatosa showing no indication for operation was diagnosed by histopathological and radiological examinations. He was treated with trastuzumab, docetaxel, and S-1 combination chemotherapy. At the end of the second course of therapy, the primary lesion was remarkably decreased in size and was associated with a significant decrease in serum AFP level. No serious adverse events occurred except for grade 3-4 leukopenia and neutropenia. We carried out eight courses of chemotherapy. Trastuzumab, docetaxel, and S-1 combination chemotherapy promise to be one of the effective treatments for HER2-positive and AFP-producing gastric cancer that have no indication for radical cure excision.
authors.affiliation: Dept. of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Japan.
authors.forename: Ichiro
authors.initials: I
authors.lastname: Amano
authors.forename: Naoki
authors.initials: N
authors.lastname: Sawai
authors.forename: Chiemi
authors.initials: C
authors.lastname: Mizuno
authors.forename: Yukie
authors.initials: Y
authors.lastname: Shaura
authors.forename: Masatake
authors.initials: M
authors.lastname: Nishiwaki
authors.forename: Ryuji
authors.initials: R
authors.lastname: Horimoto
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Oya
authors.forename: Ryusuke
authors.initials: R
authors.lastname: Kato
authors.forename: Kojiro
authors.initials: K
authors.lastname: Seki
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Hashimoto
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Amakata
authors.forename: Junko
authors.initials: J
authors.lastname: Matsumoto
authors.forename: Izumi
authors.initials: I
authors.lastname: Tanaka
authors.forename: Masayuki
authors.initials: M
authors.lastname: Mizuno
authors.forename: Toshihide
authors.initials: T
authors.lastname: Shima
authors.forename: Takeshi
authors.initials: T
authors.lastname: Okanoue
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077143:Docetaxel; D004338:Drug Combinations; D006801:Humans; D008297:Male; D010094:Oxonic Acid / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D013274:Stomach Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000378:metabolism; D043823:Taxoids / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage; D000068878:Trastuzumab; D000509:alpha-Fetoproteins / Q000096:biosynthesis
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000077143:Docetaxel; D004338:Drug Combinations; D010094:Oxonic Acid; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D005641:Tegafur; D000068878:Trastuzumab; D000509:alpha-Fetoproteins; C079198:S 1 (combination); C508053:ERBB2 protein, human